| | | Diosmin group
| Control group
| value |
| | Male (, %) | 76, 50.7% | 73, 48.7% | 0.729 | | Age (years, mean ± SD) | 41 ± 6.5 | 42 ± 7.4 | 0.215 | | Treatment course (months, mean ± SD) | 4 ± 1.4 | 4 ± 1.5 | 1.000 | | Duration of pain (, %) | | | | | <3 months | 45, 30.0% | 47, 31.3% | 0.909 | | 3–12 months | 62, 41.3% | 65, 65% | | 13–36 months | 29, 19.3% | 27, 18.0% | | >36 months | 14, 9.3% | 11, 7.3% | | Pretreatment with opioids (, %) | | | | | None | 118, 78.5% | 114, 76.0% | 0.849 | | <60 morphine equivalents/day | 21, 14.0% | 23, 15.3% | | ≥60 morphine equivalents/day | 11, 7.3% | 13, 8.7% | | Current smoker (, %) | 21, 14.0% | 23, 15.3% | 0.744 | | Obesity (, %) | 23, 15.3% | 25, 16.7% | 0.753 | | Level of lesion (culprit nerve root, , %) | | | | | L2-3/L3 | 9, 6.0% | 11, 7.3% | 0.788 | | L3-4/L4 | 13, 8.7% | 15, 10.0% | | L4-5/L5 | 99, 66.0% | 101, 67.3% | | L5-S1/S1 | 29, 19.3% | 23, 15.3% | | Baseline pain scores (mean ± SD) | | | | | VAS | 89 ± 11 | 91 ± 4 | 0.037 | | RM-Q | 17.2 ± 2.7 | 17.4 ± 2.3 | 0.490 | | NRS | 7.8 ± 0.7 | 7.8 ± 0.3 | 0.222 | | Number of patients with serious pain given diclofenac (, %) | 6, 3.9% | 5, 3.3% | 0.759 |
|
|
